- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- letrozole, zoledronic acid
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2785–2808
of 21,412
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Esophageal Neoplasm
- Interventions
- UFT (Tegafur/Uracil)
- Drug
- Lead sponsor
- Edelman, Martin, M.D.
- Individual
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
- Interventions
- ESK981
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Madison, Wisconsin
- Conditions
- Rabies
- Interventions
- CL184, HRIG, Placebo matching CL184
- Biological
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor, Pediatric Tumors, Neurocutaneous Melanocytosis, Congenital Melanocytic Nevus, Arachnoid Cysts, Astrocytoma, Ependymoma, Melanoma
- Interventions
- Mirdametinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 40 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hodgkin Lymphoma
- Interventions
- Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Uveitis
- Interventions
- Izokibep, Prednisone/Prednisolone
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Palo Alto, California • Hagerstown, Maryland + 1 more
- Conditions
- Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female
- Interventions
- Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- bryostatin 1
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Atopic Dermatitis
- Interventions
- Tapinarof cream, 1%
- Drug
- Lead sponsor
- Organon and Co
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Thousand Oaks, California • Centennial, Colorado • Coral Gables, Florida + 6 more
- Conditions
- Progressive Metastatic Castrate Resistant Prostate Cancer
- Interventions
- Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- BB-10901
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Ocoee, Florida • Springfield, Massachusetts + 8 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 34
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 23 more
- Conditions
- Melanoma
- Interventions
- Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tiragolumab, RO7247669 600 mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Tampa, Florida + 1 more
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- irinotecan-eluting beads, hepatic artery embolization
- Combination Product · Procedure
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Interventions
- EF5, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Tissue Oxygen Measurement
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 2
- States / cities
- Durham, North Carolina
- Conditions
- Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell Lymphoma
- Interventions
- golcadomide, Obinutuzumab, Polatuzumab, Glofitamab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioma
- Interventions
- Temozolomide and Bevacizumab
- Drug
- Lead sponsor
- Kentuckiana Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Taletrectinib, Placebo
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Prevention of Hair Growth
- Interventions
- 1% topical cidofovir, 3% topical cidofovir, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Migraine
- Interventions
- BHV-3500 (zavegepant), Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 116
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 88 more
- Conditions
- HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- Romidepsin, Abraxane
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Proton Accelerated Partial Breast Irradiation
- Radiation
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 50 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide, radiation therapy, Ascorbic Acid
- Drug · Radiation
- Lead sponsor
- Bryan Allen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa